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 7	  
ABSTRACT: 8	  
Venous access catheters used in clinics are prone to biofilm contamination, contributing 9	  
to chronic and nosocomial infections. So far, biofilm physiology was mostly studied in 10	  
vitro, due to a relative lack of clinically relevant in vivo models. Here, we provide a 11	  
relevant protocol of totally implantable venous access port (TIVAP) implanted in rats. 12	  
This model recapitulates all phenomena observed in clinic and allows studying bacterial 13	  
biofilm development and physiology.	   After TIVAP implantation and inoculation with 14	  
luminescent pathogens, in vivo biofilm formation can be monitored in situ and	   biofilm 15	  
biomass can be recovered from contaminated TIVAP and organs. We used this protocol 16	  
to study host responses to biofilm-infection, to evaluate preventive and curative anti-17	  
biofilm strategies, and to study fundamental biofilm properties. For this procedure, one 18	  
should expect ~3h00 of hands-on time including the implantation in one rat followed by 19	  
in situ luminescence monitoring and bacterial load estimation. 20	  
 21	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   2	  
INTRODUCTION: 1	  
	  2	  
Medical devices such as peripheral or central venous catheters, urinary catheters or 3	  
prostheses are nowadays essential to modern medicine and greatly improve patients’ 4	  
healthcare. These devices are however prone to contamination by microbial pathogens 5	  
leading to biofilm formation and biofilm-related infections that are extremely difficult to 6	  
eradicate due to the high tolerance of biofilms towards antibiotics and host immune 7	  
defenses 1. Currently, there is no efficient method for early biofilm detection, prevention 8	  
or eradication besides traumatic and costly removal or replacement of contaminated 9	  
devices2-5. Therefore, there is a dire need for specific and timely detection of biofilm 10	  
formation on medical devices. However, the development of new strategies aiming at 11	  
prevention or eradication of chronic and nosocomial biofilm infections require relevant 12	  
biofilm models and approaches to provide a better understanding of the dynamics of 13	  
biofilm formation and physiology.	  14	  
 15	  
Device associated biofilm animal models  16	  
A large number of in vitro models have been used to study biofilm formation and 17	  
physiology or for large-scale anti-biofilm drug screening6-11. Although useful, these in 18	  
vitro models do not reproduce the complex interactions occurring in the device-19	  
associated infection milieu comprising microorganisms, the host and the contaminated 20	  
abiotic surface. These therefore do not provide access to important parameters when 21	  
characterizing pathogenic biofilms, host factors and other biotic signals. By contrast, only 22	  
few in vivo models have been developed to study bacterial biofilm formation associated 23	  
with central venous catheter (CVC). One of the first corresponding models used vascular 24	  
catheter inserted in the jugular vein of rat and was developed to study Staphyloccus 25	  
aureus and Staphyloccus epidermidis biofilm-related infections and to evaluate the 26	  
efficacy of several antimicrobial agents, including antibiotics and anti-microbial peptides 27	  
7,10-15. Other CVC models using different hosts include a mice model catheterized in the 28	  
jugular vein used to study the role of alternative SigB in S. aureus virulence 16, or a pre-29	  
catheterized (jugular vein) mice model to study the eradication efficacy of lysostaphin 30	  
against S. aureus biofilm 17. Using rabbit, port access venous catheters inserted in the 31	  
jugular vein were used to test several antibiotic against S. aureus 18. Finally, several 32	  
animal models were also developed to study Candida albicans biofilm-related infections, 33	  
an important causative agent of CVC-related infections 19-22. All these studies were 34	  
invasive in nature and required animal killing in order to assess and quantify colonization 35	  
and infection. As an alternative to these CVC models where the catheter is inserted in 36	  
	   3	  
the vascular circulation, subcutaneously implanted mice CVC biofilm models were 1	  
described using luminescent variants of S. aureus, S. epidermidis and Pseudomonas 2	  
aeruginosa for real-time monitoring of biofilm formation 23,24 and dissemination 25. 3	  
However, these models do not adequately reflect real clinical situation and do not take 4	  
into account key host factors such as venous blood circulation or humoral factors. 5	   	  6	  
Overview of the proposed in vivo catheter biofilm model protocol 7	  
To better understand device associated biofilm infections, our laboratory has optimized a 8	  
long-term central venous catheter model using commercial pediatric Totally Implantable 9	  
Venous Access Ports (TIVAP) inserted in rat jugular veins 26-28. Unlike other venous 10	  
catheters used in other in vivo studies, TIVAP are closed devices accessible through a 11	  
port implanted subcutaneously and connected to the central venous system via a 12	  
catheter usually inserted into the jugular or subclavian vein. In our model, the TIVAP is 13	  
subcutaneously implanted with the port secured in a pocket, at the dorsal midline 14	  
towards the end of thoracic vertebrae. Luminescent variants of clinically relevant bacteria 15	  
forming biofilm on biomaterial are introduced into the port by puncturing the silicone 16	  
septum using Huber needles. Then, bacterial colonization and biofilm formation is 17	  
monitored, without further invasive intervention, as a function of luminescence using 18	  
charge-coupled device (CCD) camera. We optimized the inoculum size to be 1 x 104 19	  
CFU/50 µL per port for E. coli and 1 x 106 CFU/50 µL S. aureus and P. aeruginosa. 20	  
Increased bioluminescence signals were correlated to higher bacterial titers within 21	  
TIVAP. At these dosages we were able to measure the signals associated with chronic 22	  
biofilms up to 120 days. This animal model was successfully used to study the 23	  
colonization of venous catheters by clinically relevant pathogens (S. aureus, S. 24	  
epidermidis, P. aeruginosa and E. coli) 26-30. 25	  
Biofilm biomass formed in the TIVAP can be determined quantitatively by harvesting the 26	  
bacteria as discussed in details below and plating on suitable agar plates. Counts of 27	  
viable bacteria ranging from 7.6 to 8.3-log CFU/mL (port) and 7.5 to 9.2- logs CFU/mL 28	  
(catheter) were obtained in the TIVAP. The bacterial load in the organs (lungs, heart, 29	  
spleen, kidneys, liver or blood) can also be determined by plating tissue homogenates. 30	  
To complement microbiological methods assessing biofilm pathogenesis in the rat 31	  
TIVAP model, electron microscopy was used in order to visualize biofilm structures 32	  
growing on the lumen of the catheter and on the silicone septum of the TIVAP. 33	  
Furthermore, we also optimized cyclophosphamide-based immunosuppression to study 34	  
the consequences of TIVAP-associated biofilm infection in immunocompromised hosts. 35	  
	  36	  
	   4	  
Relevance and applications of the in vivo TIVAP biofilm model 1	  
 2	  
We showed that our TIVAP rat model recapitulates all phenomena observed in clinical 3	  
TIVAP-associated biofilm infections and can also be used to study the fundamental 4	  
mechanisms of in vivo biofilm formation. 5	  
 6	  
TIVAP applications from a clinical point of view: 7	  
1. Evaluation of current procedures used to handle TIVAP in clinical settings, 8	  
including skin disinfection procedures, TIVAP patency maintenance 26, etc. 9	  
2. Study of the different routes of TIVAP colonization in addition to classical endo-10	  
luminal colonization including: 11	  
i/ extra-luminal colonization of the catheter; 12	  
ii/ extra-luminal colonization of the port leading to subcutaneous port pocket 13	  
infection, a clinical situation where repeated intradermal needle punctures during 14	  
access to TIVAP may lead to subcutaneous bacterial port pocket infection 31 15	  
(20% of TIVAP-implanted rats inoculated with P. aeruginosa or S. aureus 16	  
developed subcutaneous infection around port 27); 17	  
iii/ catheter tip colonization via hematogenous route of infection, a situation 18	  
observed when TIVAP implanted patients suffer from bloodstream infection: 19	  
TIVAP implanted rats injected with S. aureus in the tail vein showed colonization 20	  
of TIVAP catheter tip 27. Furthermore, we observed, in our TIVAP rat model, 21	  
chronic colonization of implanted devices with occasional catheter-related 22	  
bloodstream infections as detected in CVC bearing patients 27. Thus, our rat 23	  
TIVAP model successfully reproduced clinical situations such as biofilm-related 24	  
bloodstream infections, organs colonization and port-pocket infections.  25	  
3. Investigation of controlled chronic infection and recurrence of infection after 26	  
conservative treatment.  27	  
4. Development of early biofilm detection methods (“biofilm biomarkers”). Such 28	  
biomarkers are currently lacking and their identification could strongly facilitate 29	  
medical decisions. 30	  
5. Evaluation of prophylactic strategies including: 31	  
 i/ novel catheter lock solutions. The catheter lock therapy corresponds to the use 32	  
of highly concentrated antimicrobial (often antibiotic) solutions that dwell inside 33	  
the catheter for at least 12 to 24 hours 32; 34	  
ii/ catheter treatment with anti-adhesive procedure 26. We modified the surface of 35	  
commercial TIVAPs composed of silicone and titanium, using methyl cellulose 36	  
(MeCe) as well as polyethylene glycol (PEG), two macromolecules with 37	  
	   5	  
described anti-adhesive activities 33,34. Using our rat model of biofilm infections 1	  
inoculated with bioluminescent bacteria, we showed that an anti-adhesive 2	  
approach could constitute an efficient prophylactic strategy to control infections in 3	  
medical devices; 4	  
iii/ anti-biofilm strategies against biofilm-related infection such as vaccination.  5	  
6. Evaluation of curative strategies against difficult-to-treat pathogens (P. 6	  
aeruginosa, methicillin resistant S. aureus, possibly C. albicans), for which the 7	  
current clinical recommendation in case of device-related infection is costly and 8	  
traumatic removal of the device. These curative strategies include: 9	  
i/ curative catheter lock solutions active on already developed infectious biofilms 10	  
27,28,30. We used EDTA as adjuvant in combination with gentamicin as a lock 11	  
solution to eradicate all the bacterial biofilms tested using our rat TIVAP model 28 12	  
and L-arginine, a basic amino-acid, combined with gentamicin to eradicate S. 13	  
aureus and E. coli in vivo biofilms 30; 14	  
ii/ novel anti-biofilm molecules; 15	  
iii/ alternative strategies (ultrasonic waves, photodynamic or phage therapies).  16	  
7. Evaluation of anti-thrombotic treatments since thrombosis is observed using this 17	  
model 26. Previous studies showed that biofilm colonized implanted catheters are 18	  
at higher risk of causing thrombosis 35. We used our model to demonstrate the 19	  
better patency in the TIVAP coated with anti-adhesive coatings compared to 20	  
control untreated TIVAPs 26. 21	   	  22	  
TIVAP applications from a fundamental point of view: 23	  
1. Study of biofilm physiology in vivo and in a clinically relevant model amenable to 24	  
transcriptomic, proteomic or metabolomic analyses. Biofilm-specific properties 25	  
such as biofilm-associated production of molecules 29 or biofilm-specific increased 26	  
recalcitrance to antimicrobial agents and to the immune system can be studied 27	  
using this model.  28	  
2. Evaluation of the in vivo role of biofilm-promoting factors identified in vitro. 29	  
3. In vivo study of clinically relevant biofilm-forming microorganisms other than 30	  
bacteria, in particular C. albicans, one of the main causes of catheter-related 31	  
infection. 32	  
4. Investigation of the impact of the implanted host immune system on the 33	  
development of in vivo biofilms 27 and, reciprocally, study of the impact of biofilm 34	  
development on the immune system. 35	   	  36	  
	   6	  
	  1	  
Experimental Design 2	  
 3	  
Overview of the procedure stages 4	  
The procedure described is designed to study bacterial biofilms using a central venous 5	  
catheter called TIVAP inserted in rat jugular vein. The study can be broadly divided into 6	  
6 stages (see Flow chart of the different steps is presented in Figure 1): One animal 7	  
study takes between 2-3 weeks but may be longer depending on the question to be 8	  
addressed, for example immunosuppression of animals will add another 4 days to a 9	  
study. A trained engineer, PhD student, post-doctoral fellow or researcher can perform 10	  
all stages of the procedure.  11	  
 12	  
1) Pre-surgical procedures: After reception of the rats, they are transferred 2 per cage 13	  
and housed in animal facility. They are given pain-killers in specialized gels prior to 14	  
surgery. 15	  
2) Surgery (TIVAP implantation): TIVAP is implanted subcutaneously with catheter 16	  
inserted into the jugular vein. 17	  
3) Postsurgical care: Animals are allowed to recover from surgery before injecting 18	  
bacteria in the port. During this time of recovery, the patency of TIVAP is maintained by 19	  
“flush and draw” technique to mimic clinical TIVAP use, and the temperature and weight 20	  
of the animals are regularly monitored. 21	  
4) Bacterial challenge: Four days post-surgery, TIVAP is contaminated via controlled 22	  
bacterial inoculation through the port by bacteria that are allowed to adhere to the device 23	  
surface (internal) for certain duration of time before the inoculum is removed. 24	  
5) Post challenge care and monitoring: The biofilm is allowed to form on the device up to 25	  
day1, day4, day10 or even up to 120 days, depending on the question addressed. Blood 26	  
sampling is done at day 0 (before inoculation to ensure TIVAP sterility); day4 and day8 27	  
to analyze the TIVAP mediated infection. Animals are monitored for the clinical 28	  
symptoms. 29	  
6) Euthanasia and sampling: On the day of experiment termination, animals are 30	  
euthanized and the TIVAP and organs are aseptically removed for analysis.  31	  
	  32	  
Laboratory facilities 33	  
All the described animal work was done in the Institute Pasteur animal facilities, which 34	  
are accredited by the French Ministry of Agriculture to perform experiments on live 35	  
rodents (accreditations A75-15 27, issued 12 November 2004, and A75-15 04, issued 22 36	  
	   7	  
May 2008). Work on animals was performed in compliance with French and European 1	  
regulations on care and protection of laboratory animals (European Commission 2	  
directive 2010/63; French law 2013-118, 06th February, 2013). The protocols used in 3	  
this study were approved by the ethics committee of “Paris Centre et Sud N°59” 4	  
(reference 2012-0045).	   All methods are performed in a ‘Biosafety Level-2’ facility, 5	  
containing a Class II biosafety cabinet. Aseptically collected samples (TIVAP, organs or 6	  
blood) from animals can be processed in the main laboratory inside a Class II biosafety 7	  
cabinet to maintain sterility. The animal room is cleaned with disinfectant every day until 8	  
the end of a study. 9	  
 10	  
Controls 11	  
Proper controls must be used in the study. For each study, uninfected animal control 12	  
with implanted TIVAP should be used as biofilm negative controls. For testing 13	  
antimicrobials, 1X PBS or other appropriate reagent control must be used to compare 14	  
the efficacy of the tested compounds. 15	  
 16	  
Anesthesia optimization 17	  
Anesthetics are critical to sedate rat and reduce discomfort during surgery as well as 18	  
during follow-up procedures. For example, rats treated with cyclophosphamide have 19	  
different susceptibilities to anesthesia (isoflurane) induced hypoxia; therefore, empirical 20	  
determination of chemical anesthesia and/or isoflurane dosages is required. We have 21	  
optimized ketamine, xylazine and acepromazine mix (7:2:1, v/v) injected intraperitoneally 22	  
to 500 µL cocktail/300grams of rat weight. Acepromazine keeps the rats calm and allows 23	  
additional injections during the surgery, if needed. Isoflurane concentration for healthy 24	  
rats was optimized to 3% for the induction of anesthesia and maintenance of the 25	  
anesthetic state at an oxygen flow-rate of 0.8 L/min and air flow-rate of 0.4 L/min to get a 26	  
total debit of 1.2. Isoflurane concentration for immunosuppressed rats was optimized to 27	  
1.5%-2.0% for the induction of anesthesia and 1.5% for maintenance of the anesthetic 28	  
state at an oxygen flow-rate of 0.6 L/min and air flow-rate of 0.4 L/min to get a total debit 29	  
of 1.0 L/min. 30	  
 31	  
Critical step: Isoflurane is an inhalation anesthetics found under several trade names 32	  
such as aerrane, floran, florane, isothane etc. It provides a quick, easy and long lasting 33	  
effect when provided continuously to the research animals. Prolonged exposures in 34	  
animals need to be regulated and monitored closely to prevent death. Injectable 35	  
anesthetics, such as ketamine–xylazine-acepromazine mixture can be used for long-36	  
	   8	  
term (up to 45 min) sedation of rats. Ketamine and acepromazine are controlled 1	  
substances, which require secured storage and proper records of usage. 2	  
CAUTION: Isoflurane is a halogenated ether. It is a colorless liquid anesthetic with a 3	  
pungent odor. High doses of isoflurane exposure in research animals have been 4	  
demonstrated to have fetal toxic effects. Pregnant women are recommended not to use 5	  
it unless other means of anesthesia are not available and, in such case, special masks 6	  
need to be worn. Only an approved anesthetic respirator system approved by the ethical 7	  
committee should be used. Also make sure to work in well-ventilated area when using 8	  
isoflurane or any other inhalation anesthetics. 9	  
 10	  
Choice of Animals 11	  
We chose Crl:CD/SD variant of wistar rats for our study as they are recommended for 12	  
studying infectious diseases. The rats are 250-275 grams at reception day and gain ~50 13	  
grams by the day of surgery.  14	  
Note: Wistar rats may also be used for the study. 15	  
 16	  
Choice of Microbes 17	  
Luminescent variants of four clinically relevant pathogens, i.e. E. coli, P. aeruginosa, S. 18	  
aureus and S. epidermidis were purchased (S. aureus Xen36, Xen30, Xen31 and S. 19	  
epidermidis Xen43 from Caliper) or gifted (P. aeruginosa Lm1, a bioluminescent 20	  
derivative of the PAK clinical strain 36 and E. coli EAEC 55989 37 transformed with stable 21	  
plasmid pAT881) 38. E. coli and P. aeruginosa strains were grown in Lysogeny broth 22	  
(LB); S. aureus Xen36 and S. epidermidis Xen43 were cultured in Tryptic Soy broth 23	  
(TSB) supplemented with 0.2% glucose at 37°C. Other relevant bacteria may also be 24	  
studied within this model. While bioluminescence is an efficient tool to follow in situ 25	  
colonization of the device and potential dissemination, it is also possible to estimate end-26	  
point bacterial load using non-bioluminescent microbial variant. 27	  
 28	  
Optimization of inoculum size and volume 29	  
The inoculum dose was optimized to 104 cells for E. coli, 106 cells for P. aeruginosa and 30	  
S. aureus. For S. epidermidis the maximum dose that could be used was 108 cells but 31	  
did not lead to bioluminescent-detectable colonization. Currently no other bioluminescent 32	  
strain of S. epidermidis is available 24. The volume of the inoculum was optimized to 33	  
50µL per TIVAP. The dead volume of the port is 250µL. This insures that no bacteria are 34	  
flushed into the blood stream at the time of inoculation. 35	  
 36	  
 37	  
	   9	  
Antibacterial agents 1	  
The described methods were successfully used in our model to test the antibiofilm 2	  
activity of cefazolin, gentamicin, EDTA, ethanol (70%) and L-arginine, injected alone or 3	  
in certain combination in catheter lock solutions 27,28,30. Moreover, our model was 4	  
successfully used to evaluate the anti-adhesion characteristics of biomimetic glycocalyx-5	  
like polymer such as methylcellulose 26. Empirically, the effect of any relevant 6	  
antimicrobial agents or anti-adhesive molecules can be evaluated using our model. In 7	  
vitro concentration of the antimicrobial agents and procedures to graft anti-adhesive 8	  
molecules on silicone and/or titanium need to be verified before in vivo evaluation in rat 9	  
TIVAP model. 10	  11	  
	   10	  
	  1	  
MATERIALS 2	  
Reagents: 3	  
 4	  
Product Reference Manufacturer 
Sterile 1X Phosphate buffered Saline 
(PBS) 
10010-023 GIBCO 
Sterile water 15230-071 GIBCO 
Kanamycin B5264-1G Sigma Aldrich 
Cefazolin C5020-
500MG 
Sigma Aldrich 
Vancomycin 94747-5G Sigma Aldrich 
Gentamicin G1914-5G Sigma Aldrich 
Lysogeny Broth (LB) 12795-027 Invitrogen 
L-arginine A5006-100G Sigma Aldrich 
Agar degranulated 214530 DIFCO 
Tryptic Soy broth (TSB) 211825 DIFCO 
Tryptic soy agar (TSA) 236950 DIFCO 
Ethanol, 70% (made from absolute 
alcohol) 
34935-1L Sigma Aldrich 
Sterile Heparin, 500IU/mL, 5mL bottle,  512507 Sanofi Aventis 
Ketamine, Imalgen1000 IMA004 Merial SAS Lyon, Fr 
Xylazine, (Rompun™2%) ROM001 Bayer Healthcare, 
Germany 
Acepromazine (Injectable), Calmivet 
Solution 
CAL226 Sanofi Aventis, 
Lure, FR 
Betadine gel 10%, tube of 100g  Meda Pharma 
Anesderm 5%, tube of 5g Pharmacy Pierre Fabre, 
France 
Betadine solution, bottle of 120mL  Vetoquinol 
Eye drops, Ocrygel® 843TVN  
Gel, medigelsucralose 56gm TPP2270 Fisher Scientific 
Vikron® 1%  Reltyon 
Sodium pentobarbital, Dolethal 6847542 Alcyon France 
Isoflurane, IsoVet 1000mg/g inhalation 
vapour (Schering-Plough) 
IsoVet 
1000mg/g 
Imaxio, France 
	   11	  
Buprecare® (Ibuprofen)  Axience, France 
Cyclophosphamide monohydrate C0768-5G Sigma Aldrich 
Sodium Cacodylate Trihydrate C0250-100G Sigma Aldrich 
Ruthenium red R2751-1G Sigma Aldrich 
Glutaraldehyde 25% G5882 Sigma Aldrich 
 1	  
Equipments:  2	  
Equipments (number needed for the study) Catalogue 
number 
Manufacturer 
Charged-coupled device CCD Camera (IVIS 
100) 
 Xenogen 
Corporation, 
Alameda, 
CA, USA 
Vet abc ABC vet 2.0 SCIL, 
Germany 
Surgical hood FASTER 
FLOWFAST 
H18 
Faster-air, 
France 
Laminar air flow Faster 
BH2006 
Faster-air, 
France 
Hot bead sterilizer 18000-50 Fine Science 
Tools (FST) 
Beads 18000-51 FST 
Micro spring scissors (1) 15007-08 FST 
Fine scissors (1) 14502-14 FST 
Fine forceps (2) 11245-30 FST 
Blunt forceps  (1) 11000-14 FST 
Hemostats (2) 130008-12 FST 
Silk Thread, 22.5 meters 18020-30 FST 
Curved forceps 91197-00 FST 
Suture Vicryl 3-0 Polyglactin absorbable, box 
of  36  
V497H Ethicon 
Suture Dafilon 3/0 Polyamide non-absorbable, 
box of 36 
C0935239 B Braun 
Scalpel 0510 Swann-
Morton 
	   12	  
TIVAP, Polysite 2000 micro, 5F 2105 ISP Perouse 
medical 
Sterile champ CSO-02NT LCH 
Sterile gloves (size 7-8, medium) STP641 LCH 
Sterile gauze pad CNST-470 LCH 
Huber needle, straight 7/10, 22G, 30mm, box 
of 50 
512507 Perouse 
Medical 
Respiratory Mask, FFP2 19-130-4825 Fisher 
Scientific 
Sterile gown 98000622 Barrier, 
France 
Temperature Controller, with rectal probe TCAT-2LV Physitemp 
Instruments 
Inc, USA 
Thermocage, animal warming system MK3 Datestand 
Ltd., 
Manchester, 
UK 
IPTT-300, Electronic chip introducer and chip BV 11059 PLEXX, 
Europe 
Wireless Reader with round IMI probe DAS-7006R PLEXX, 
Europe 
Mozer Max45 clipper 1245-0066 Moser 
animalline 
Isoflurane vaporizer, TAG TAG1100 TEM 
(Lormont, 
France) 
Conical tubes , 50mL 14-432-22 Fisher 
scientific 
Conical tubes , 15mL 14-959-70C Fisher 
scientific 
Microtubes 05-402-24B Fisher 
scientific 
GentleMACS™ Octo Dissociator 130-095-937 Miltenyi 
Biotec 
GentleMACS™ M tubes 130-096-335 Miltenyi 
	   13	  
Biotec 
Cell strainer 70µm Nylon 3523350 BD Falcon 
T25 digital ULTRA-TURRAX® homogenizer  0010001502 Ika, France 
NEYtech Ultrasonik, 44–48 Khz  NEYtech 
 1	  2	  
	   14	  
 1	  
PROCEDURE 2	   	  3	  
Step 1: Pre-surgical Procedures 4	  
1A) Day -6, reception of animals: The CD/SD (IGS:Crl) male rats (CharlesRiver) weigh 5	  
275–300grams and are acclimatized to a 12 h day/night cycle for one week prior to use 6	  
with commercial feed / tap water ad libitum. (TIMING: Responsibility of Animal Facility) 7	  
 8	  
1B) Day -5, an electronic chip is inserted in the flank region of rats to monitor the 9	  
temperature during course of the study. The weight of rats is also monitored on regular 10	  
basis. (TIMING: 10 min per rat) 11	  
 12	  
1C) Day -2, all the rats are fed with Medigel-sucralose (1cup (56gm) per cage per day) 13	  
without ibuprofen* for rats to habituate to mixture followed by Medigel+ibuprofen gel on 14	  
day -1. (TIMING: 10 min per rat) 15	  
Critical step: if given directly with the drug, most of the rats do not eat the pain-killer and 16	  
can lead to health issues post-surgery. Medigel with ibuprofen can be prepared on day -17	  
2 and stored at 4°C but brought to room temperature before feeding the rats. 18	  
	  19	  
Step 2: Surgical Procedure (TIVAP implantation, day 0) (TIMING: ~ 55min) 20	  
2A) Anesthesia (TIMING: 2 minutes per rat, 5-6 minutes for a rat to sleep) 21	  
Rats are anesthetized using a 500µL cocktail (per 300grams of rat weight) of ketamine, 22	  
xylazine and acepromazine mix (7:2:1, v/v) injected intraperitoneally. 23	  
 24	  
2B) Shaving (TIMING: 3-4 minutes per rat) 25	  
Once the rat is fully unconscious, closely shave dorsal side of the rat with an electric 26	  
clipper to remove hair from the neck up to lower end of the thoracic vertebrae and from 27	  
left to right end of the body (Figure 2). Then, turn the rat on its back and shave the 28	  
neckline carefully without cutting the skin. Remove any excess hair with the help of a 29	  
clean paper towel. 30	  
Critical step: If the rat is not completely asleep, any procedure including shaving can be 31	  
stressful leading to death of rat during the procedure. 32	  
 33	  
2C) Disinfection: (TIMING 5 minutes per rat) 34	  
Transfer the rat on a sterile sheet. The shaved area (both dorsal and ventral sides) as 35	  
well as surrounding area is gently cleaned in 2 steps: i) wash with betadine soap using a 36	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sterile gauze pad or any other sterile pad of absorbent material; ii) disinfect with betadine 1	  
solution. Repeat the cycle 3 times. 2	  
 3	  
2D) Preparation for surgery: (TIMING ~15 minutes) 4	  
Since it takes ~15 minutes for a rat to be ready for surgery, meanwhile, arrange and 5	  
prepare the surgery area. For this,  6	  
2D.1) Clean the surgical hood with 70% ethanol and spread a sterile champ/sheet.  7	  
2D.2) On the sheet, place on left corner a pair of Scissors, hemostats (2), spring 8	  
scissors, fine forceps (2), 2 pieces of silk thread around 20 cm long, curved forceps, 9	  
sterile gloves, TIVAP (with its kit open), scalpel and on the right hand side keep sterile 10	  
gauze pad, a syringe with 1X PBS (50mL, from the TIVAP kit), vicryl suture, 11	  
monofilament suture, 1 mL syringe filled with 1X PBS with Huber needle (from the 12	  
TIVAP kit) and 1mL syringe filled with sterile 300µL heparin.  13	  
2D.3) Turn on 37°C thermo-cage system for storing the rat after surgery. 14	  
2D.4) Turn on instrument sterilizer. 15	  
Critical step: keep everything you need for the surgery handy as the rats may start to 16	  
wake up in case of delay in the process of surgery and may be stressed. 17	  
 18	  
2E) Surgery: (TIMING ~30-45 minutes per rat, Figure 2 and Figure 3) 19	  
2E.1: Once the rat is disinfected, place the rat on the surgical sheet with the dorsal 20	  
side up and tail away from you. Take some 70% ethanol and wipe the body of the 21	  
rat once more. Wear the sterile gloves and avoid touching any surroundings. 22	  
2E.2: Make an incision (~1.5cm) on dorsal line at the upper end of thoracic 23	  
vertebrae with a scalpel.  24	  
2E.3: Using a scissor, make a subcutaneous pocket inside the incision by opening 25	  
& closing the scissor slowly. Make the pocket big enough to easily insert the port of 26	  
TIVAP.  27	  
2E.4: Take the port and insert the pointed end first while pushing the wider part 28	  
with your thumbs. Once inserted, secure the TIVAP by suturing (using a hemostat 29	  
to hold the suture and a blunt forceps) inside of the skin with vicryl, 3.0, non-30	  
absorbable suture. 31	  
2E.5: Insert Huber needle into the port by puncturing the septum and gently turn 32	  
the rat on its back. Place a pad of gauze pad wet in 1X PBS. 33	  
Critical step: It is important to keep a wet pad of gauze pad on the incision 34	  
throughout the process to prevent its dehydration. 35	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2E.6: Make an incision about 1-1.5cm in the neck on right hand side with scalpel. 1	  
Gently try to remove the muscles with a fine forceps to expose the vein. Keep the 2	  
area wet and clean with 1X PBS. 3	  
2E.7: Locating the vein: Left Jugular vein is situated superficially under the salivary 4	  
glands and it forms “inverted Y” junction with the right jugular vein, tail of “inverted 5	  
Y” joining the subclavian vein. Keep the area and veins wet with 1X PBS, all the 6	  
time. 7	  
Critical step: It is important to keep the vein wet because if dried it will lose its 8	  
flexibility and it will be difficult to make a cut in the vein as well as tough to insert 9	  
the catheter in vein. 10	  
2E.8: Using a curved forceps pass two black silk threads under the external jugular 11	  
vein. Clamp one on the proximal end (to tie the incised vein) and another on the 12	  
distal end (to secure the catheter inside the external jugular vein) of the jugular 13	  
vein with hemostats.  14	  
2E.9: Then, try to clean the area surrounding the vein and remove any extra 15	  
tissues that might be attached to jugular vein. Keep the vein and surrounding area 16	  
wet with 1X PBS.  17	  
2E.10: After exposing the vein, slightly tilt the rat (gently) and insert the blunt end 18	  
of tunneling rod (provided in the TIVAP kit) from the dorsal side and push out from 19	  
the ventral incision in the neck region. On the pointed end put on the catheter and 20	  
pull it along the tunneling rod on ventral side so as to have catheter tunneled under 21	  
the skin ready to be inserted in the jugular vein. 22	  
2E.11: Cut the catheter to a length of 4.5 cm (catheter has markings 1cm apart) at 23	  
an angle not more than 30°. This is the length of catheter to be inserted in the 24	  
external jugular vein to reach the top of right atrium. 25	  
Critical step: Cutting the catheter at a higher angle will allow easy insertion of 26	  
catheter in the jugular vein but it will lose patency quickly due to suction of vein 27	  
against the bigger tilted cut while pulling the blood with syringe.  28	  
2E.12: Make sure that port and catheter are filled with 1X PBS. For this, fill the 29	  
TIVAP by slowly pushing the piston of the syringe with Huber needle inserted in to 30	  
port. 31	  
Critical step: It is important to make sure before inserting the catheter in jugular 32	  
vein that there is no air in the TIVAP as it can kill the rat within few minutes. 33	  
2E.13: While gently holding the vein with a fine forceps make a partial cut in the 34	  
external jugular carefully using a micro spring scissors. 35	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Critical step: There may be lots of blood flow from the vein. In this case take wet 1	  
gauze pad and press it against the vein for 2-3 minutes or until the bleeding has 2	  
stopped. Keep the vein wet using 1X PBS. 3	  
2E.14: Dilate the vein carefully by inserting closed forceps little bit. Once the 4	  
forceps is inside slowly release to open it, at the same time hold the upper part of 5	  
the incision with one forceps and insert the catheter using another forceps. Slightly 6	  
push the catheter inside the vein (~4.5cm) followed by flushing 100µL 1X PBS in 7	  
the vein. 8	  
Critical step: This step should be done as early as possible as the vein may be 9	  
dehydrated and become inflexible. This step is most tricky and need lots of 10	  
practice to insert the catheter. Furthermore there can be blood loss leading to 11	  
death of rat; hence the insertion must be quick. TROUBLESHOOT 12	  
2E.15: Try to gently draw the blood to make sure the reflux and then flush about 13	  
500-600µL 1X PBS and lock with 250µL heparin (500 IU/mL). Remove the Huber 14	  
needle form the port. TROUBLESHOOT 15	  
2E.16: Tie the black thread on the distal end on the vein to secure the catheter and 16	  
proximal thread to block the incised end of the vein. 17	  
Critical step: The thread should not be too tight as it can create pressure and 18	  
prevent the drawing of blood. Also, it should not be lose as the catheter may slip 19	  
out of the vein. 20	  
2E.17: Clean the surgery area and suture dorsal (4-5 stitches) and ventral (3-4 21	  
stitches) incisions. Put antiseptic cream such as betadine and local anesthetic 22	  
lidocaine cream such as Anesderm. 23	  
2E.18: Transfer the rat to 39°C chamber until wakes up. 24	  
2E.19: Finally, transfer the rat into a new cage with new water bottle. Place a cup 25	  
of Medigel+ibuprofen per cage.  26	   	  27	  
Step 3: Postsurgical care: Day +1 to Day +4 28	  
3A) Feeding Analgesic: New cup of Medigel + ibuprofen is kept in the cage of the rats on 29	  
day +1 after surgery. 30	  
3B) “Flush and draw”: (TIMING 4 minutes anesthesia, 5 minutes flush and draw per rat). 31	  
3B.1) To maintain the patency of the catheters, the TIVAP is flushed every day until 32	  
the day of the bacterial challenge. The rat is transferred to the isoflurane box until the 33	  
induction of anesthesia.  34	  
3B.2) Meanwhile, place a sterile sheet in the laminar air flow and place the nose 35	  
piece connected to the isoflurane system on it.  36	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3B.3) Place the nose of the anesthetized rat in the nose piece such that the tail is 1	  
away from you.  2	  
3B.4) Clean the skin on and surrounding the port with betadine solution and 70% 3	  
ethanol and allow to air dry for 4-5 minutes.  4	  
3B.5) Gently insert the Huber needle connected to a 2mL syringe filled with 1X PBS 5	  
into the port by puncturing silicon septum of the port.  6	  
3B.6) Slowly turn the rat on its back keeping the needle inside the port.  7	  
3B.7) Carefully inject about 100µL 1X PBS and then check blood reflux by slowly 8	  
pulling the piston of the syringe. Flush TIVAP with 1.0 to 1.5mL 1X PBS, followed by 9	  
locking the TIVAP with 250µL heparin (250IU/mL).  10	  
3B.8) Clean the skin with betadine solution and put the rat back in the cage.  11	  
Critical step: If the rat is not anesthetized completely, the movement of neck may 12	  
block the blood reflux. If isoflurane system is not available chemical anesthesia can 13	  
be given to rats. In this case 250µL anesthesia per 500 grams rat is sufficient. 14	  
TROUBLESHOOT 15	  
 16	  
3C) Clinical signs: Monitor the clinical signs such as local inflammation around the 17	  
port, weight loss and fever. If clinical signs are not normal then euthanize the rat. 18	  
Critical step: Local inflammation can be due to several reasons such as forced 19	  
injection through the port, infection or too much local injury due to surgery. 20	  
TROUBLESHOOT 21	  
 22	  
Step 4: Bacterial inoculation and monitoring of biofilm formation using 23	  
bioluminescence: Day +4 (TIMING 30 minutes per rat) (see Figure 4) 24	  
4A) Bacteria preparation: One day before bacterial challenge, start overnight culture of 25	  
bioluminescent E. coli 55989 or P. aeruginosa in Lysogeny broth and S. aureus (Xen36, 26	  
Xen30 or Xen31) or S. epidermidis Xen43 in Tryptic soy agar broth at 37°C shaking at 27	  
140rpm. 28	  
 29	  
4B) Spin 5mL culture at 7500rpm for 10 minutes to pellet bacteria and re-suspend in 30	  
5mL 1X PBS. Wash the culture twice in 5mL 1X PBS. Finally, resuspend bacteria in 5mL 31	  
1X PBS and measure optical density at 600nm (OD600nm). 32	  
 33	  
4C) Dilute the bacterial inoculum so as to inject 104 CFU/50µL for E. coli, 106 CFU/50µL 34	  
for P. aeruginosa & S. aureus Xen36 and 108 CFU/50µL for S. epidermidis Xen43. 35	  
 36	  
	   19	  
4D) Record the weight and temperature of rat before anesthesia. Clinical symptoms 1	  
such as local inflammation at the site of port or in the neck region, any other abnormality 2	  
such as breathing trouble, weight loss and fever must be recorded. Any sick rat must not 3	  
be included in the study and should be euthanized. 4	  
 5	  
4E) Anesthetize the rat as described under “flush and draw” method (see step 3B). 6	  
Meanwhile, spread the sterile sheet in the laminar air flow. Keep betadine solution, 70% 7	  
ethanol, sterile gauze pads, 50µL bacterial inoculum in 1mL tuberculin graduated 8	  
syringe, 1mL syringe attached with Huber needle and filled with 1X PBS, 1mL syringe 9	  
filled with 300µL heparin. 10	  
 11	  
4F) Anesthetized rat is transferred to the dark box of IVIS imaging system with a charged 12	  
coupled device (CCD) camera (Xenogen Corporation, Alameda, CA, USA) for monitoring 13	  
bioluminescence before bacterial challenge. 14	  
 15	  
4G) After imaging, transfer rat to the hood for infection. Place rat with its nose inside the 16	  
nose piece and tail away from you. Clean the skin on and surrounding the port with 17	  
betadine solution and 70% ethanol and allow to air dry for 4-5 minutes. Gently insert the 18	  
Huber needle connected to a 2mL syringe filled with 1X PBS into the port by puncturing 19	  
silicon septum of the port. Slowly turn rat on its back keeping the needle inside the port. 20	  
Slightly inject about 50µL-100µL 1X PBS and then check blood reflux by slowly pulling 21	  
the piston of the syringe. Remove the syringe keeping the Huber needle inside the port 22	  
and replace with a syringe to withdraw 150µL blood for analysis. Replace this syringe 23	  
also with another one containing bacterial inoculum. Slowly push inoculum into the port. 24	  
Normally this should take 2 minutes.  25	  
Critical step: If the TIVAP is not patent, do not use it for the study. The blood sample is 26	  
important to check contamination of TIVAP during the post-surgical maintenance. Care 27	  
should be taken while taking out the needle out of the port to prevent injecting yourself 28	  
with bacteria. This procedure is always done under the hood if using Class II pathogens. 29	  
Injection of inoculum must be very slow to avoid flushing bacteria into the stream. 30	  
 31	  
4H) After bacterial challenge, rat is again transferred to the dark box of IVIS imaging 32	  
system with a charged-coupled device (CCD) camera (Xenogen Corporation, Alameda, 33	  
CA, USA) for monitoring bioluminescence. The rats (with 1X PBS) are used as 34	  
uninfected controls.  35	  
 36	  
4I) Rat is then carefully placed back into the cage. Label the cage as Class II. 37	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 1	  
4J) Removal of planktonic bacteria: 3 h after bacterial inoculation, the planktonic bacteria 2	  
are removed leaving only the adhered bacteria to form biofilm. For this, repeat the 3	  
anesthesia procedure as above. Insert a Huber needle attached to a 1mL syringe 4	  
containing 500µL 1X PBS and flush 50-100µL in the TIVAP very slowly. Replace the 5	  
syringe with new 1mL syringe to withdraw about 300uL blood. Remove this syringe with 6	  
another syringe containing ~250µL heparin (500IU/ml) and lock the TIVAP. 7	   	  8	  
Step 5: Post challenge care and monitoring: (TIMING: 30 minutes per rat) 9	  
5A) Monitoring Clinical symptoms: Carefully monitor/record weight loss, fever, diet loss 10	  
or any other abnormal behavior. Any rat with temperature above 39°C +/- 0.5 or below 11	  
34°C +/- 0.5 for continuous 3 days must be euthanized. The sick rats must be 12	  
euthanized. 13	  
 14	  
5B) Bioluminescence for biofilm development and pathogenesis (see Figure 4): Biofilm 15	  
formation inside the lumen of the TIVAP and associated infection is measured as a 16	  
function of bioluminescence. Anesthetized rat (either isoflurane or chemical) is 17	  
transferred to the dark box of IVIS imaging system with a charged coupled device (CCD) 18	  
camera (Xenogen Corporation, Alameda, CA, USA) for monitoring bioluminescence. 19	  
Length of exposure can vary depending on the bacteria and the expected infection. The 20	  
exposure time can vary depending upon bacteria and infection. Normally, 1 minute 21	  
exposure is sufficient for E. coli and P. aeruginosa but for S. aureus Xen36 exposure can 22	  
be about 2-4 minutes. Control rats are exposed for the same or more time compared to 23	  
test rats.  24	  
Critical step: Exposing control rat is important to evaluate and measure background 25	  
coming from different material such as animal feed or reagents used. It is important to 26	  
use at least 4 control rats per study for statistics. 27	  
 28	  
5C) Blood sampling: Blood sampling can be done on day 4 and day 8 post-infection to 29	  
monitor the blood stream infection and associated changes in host factors such as 30	  
cytokine analysis. Blood (150µL) can be drawn either from the caudal (tail) vein or by 31	  
retro orbital plexus puncture.  32	  
5C.1) Tail vein: (TIMING: 10 minutes per rat). 33	  
Anesthetize the rat as described above. In case using chemical anesthesia, inject 34	  
only 200µL intraperitoneally as the procedure takes only 10 minutes for injection. 35	  
Clean the tail with 70% ethanol and rub the tail with a sterile gauze pad to remove the 36	  
dead scales. Approximately 5cm above the tail end insert a tuberculin needle and 37	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slowly pull the blood. Collect the appropriate volume of blood and transfer to a 1	  
collection tube containing anti-coagulant (for viable bacteria count, estimation of 2	  
immune cell population) or tube without anti-coagulant (for cytokine analysis). 3	  
5C.2) Retro orbital plexus: (TIMING: 10 minutes per rat) 4	  
Anesthetize the rat as described above. Put the rat on comfortable table. Use a 5	  
Pasteur sterile pipette to gently and slowly puncturing the orbital plexus. While firmly 6	  
holding the Pasteur pipette near the sinus, with gentle rotating movements insert the 7	  
tube through the membrane. Keep rotating the tube through the orbit until the blood 8	  
starts to flow. Collect the appropriate volume of blood and transfer to a collection tube 9	  
containing anti-coagulant (for viable bacteria count, estimation of immune cell 10	  
population) or tube without anti-coagulant (for cytokine analysis). 11	  
Critical Step: Of the circulating blood volume, approximately 10% of the total volume can 12	  
be safely removed every 2 to 4 weeks, 7.5% every 7 days, and 1% every 24 hours 39,40.  13	  
CAUTION: Technical expertise is required before performing blood sampling. Regarding 14	  
the presence of retro orbital plexus instead of sinus in rats, it is not a preferred method 15	  
and a minimum of 10 days must be allowed for tissue repair before repeat sampling from 16	  
same orbit 41.  17	   	  18	  
Step 6: Euthanasia and sampling: (TIMING ~45 minutes per rat)	  19	  
After the last day of observation by bioluminescence: 20	  
6A) Euthanasia: (TIMING ~5 minutes per rat) 21	  
Euthanize the animals using a procedure validated by the ethics committee of your 22	  
institution (CO2 or chemical euthanasia using IP injection of Dolethal (2mL/rat, 23	  
200mg/mL)). Put the unconscious rat on a sterile sheet in the laminar air flow system. 24	  
Clean the body of the rat with 70% ethanol. 25	  
 26	  
6B) Blood sampling on animals: (TIMING: ~5 min per rat) 27	  
Using a procedure validated by the ethics committee of your institution (retro-orbital 28	  
plexus/heart puncture/tail vein). The blood (volume depends on experiment planned; 29	  
100µL for CFU/mL or 200µL for cytokine analysis) is withdrawn by heart puncture. Keep 30	  
the anesthetized rat on its back on a sterile champ. Feel the heartbeat with your figure 31	  
for place with fastest beat. Insert at this point a 22G needle connected to a 1mL syringe. 32	  
Withdraw the blood slowly and transfer to a collection tube containing anti-coagulant (for 33	  
viable bacteria count, estimation of immune cell population) or tube without anti-34	  
coagulant (for cytokine analysis). 35	  
Critical Step: When blood sampling is desired, take the blood sample from rat while it is 36	  
still alive and unconscious, as withdrawing blood from the heart of dead rat is difficult 37	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due to lack of pumping. Euthanasia by Dolethal takes ~10 minutes providing 1	  
experimenter ample of time to sample blood. In case of euthanasia by CO2, first 2	  
anesthetize rat using 400µL ketamine-xylazine-acepromazine mixture to sample blood. 3	  
 4	  
6C) Organ and TIVAP sampling: (TIMING: ~10 min per rat) 5	  
Aseptical removal of each TIVAP and placement in a sterile Petri plate for imaging with 6	  
CCD camera imaging system. A set of TIVAPs can be set aside for electron microscopy 7	  
imaging (see Figure 5).  8	  
6C.1) Remove the TIVAP aseptically and put it in a labeled sterile Petri plate. 9	  
6C.2) Aseptically remove spleen, kidneys, lungs, liver and heart and transfer to Petri 10	  
plates. 11	  
6C.3) All organs and TIVAP are imaged using CCD camera for bioluminescence 12	  
signals. 13	  
 14	  
6D) Organ treatment and enumeration of bacterial load: (TIMING: ~10-15 min per rat) 15	  
All the procedure is done under the laminar air flow (P2 lab). 16	  
6D.1) After bioluminescence imaging, wash organs in 4mL 1X PBS buffer (in a 50mL 17	  
conical tube) before transferring to gentleMACS™ M tubes containing 5mL 1X PBS.  18	  
6D.2) Weigh all the organs for analyzing parameters per gram of organ.  19	  
6D.3) Homogenize the organs using gentleMACS™ M tubes with the gentleMACS™ 20	  
Octo Dissociator (Miltenyi Biotec). Alternatively, homogenization of each organ can 21	  
be done using a T25 digital ULTRA-TURRAX® homogenizer (Ika).  22	  
6D.4) Homogenized organs are passed through cell strainer (70µm nylon, BD 23	  
Falcon).  24	  
6D.5) The bacterial suspension is then diluted serially, plated on agar plates and 25	  
incubated at 37°C for colony counts. 26	  
 27	  
6E) Extraction and quantification of biofilm bacteria from TIVAP: (TIMING: ~10-15 min 28	  
per rat) All the procedure is done under the laminar air flow (P2 lab).  29	  
6E.1) TIVAP are carefully wiped with 70% EtOH before extracting intraluminal biofilm 30	  
bacteria to avoid contaminant.  31	  
6E.2) The catheter is cut into small pieces and a slit is made horizontally to expose 32	  
the lumen and transferred to a microtube containing 1 mL 1X PBS.  33	  
6E.3) The septum is removed from the port using a sterile scalpel and forceps, cut 34	  
into small pieces and transferred to a separate tube containing 1 mL 1X PBS.  35	  
6E.4) Cells attached to the titanium body of the port are scratched in 100 mL 1X PBS 36	  
and transferred to the same tube as the septum.  37	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6E.5) Biofilm that formed on the septum and in the lumen of catheter is extracted by 1	  
vigorously vortexing the tubes for 1 min, followed by transferring them to an ultrasonic 2	  
water bath (NEYtech Ultrasonik, 44–48 Khz) for 5 min and a second vortexing for 1 3	  
minute.  4	  
6E.6) The bacterial suspension is then diluted serially, plated on agar plates and 5	  
incubated at 37°C for colony counts. CFU/mL and bioluminescent signals (ROI, 6	  
p/S/cm2/sr) are plotted together for correlation. 7	  
	  8	  
Other related procedures 9	  
supp1) Port pocket infection: (TIMING ~20 min per rat) 10	  
supp1A) Any inflammation around the port after injecting the bacterial inoculum in the 11	  
port indicates a pocket infection. 12	  
supp1B) From euthanized rat, carefully remove the port from the pocket by opening the 13	  
incision made at the time of surgery. Cut the sutures used for securing the port in the 14	  
pocket.  15	  
supp1C) Image the rat in the dark box of IVIS imaging system with a charged coupled 16	  
device (CCD) camera (Xenogen Corporation, Alameda, CA, USA) for monitoring 17	  
bioluminescence and evaluate the bacterial load in the pocket. 18	  
supp1D) Remove all the pus formed in the pocket for CFU estimation. 19	  
supp1E) Plate the serial dilutions for E. coli and P. aeruginosa on LB and for S. aureus 20	  
on TSB. 21	  
 22	  
supp2) Hematogenous infection: (TIMING ~10 min per rat)  23	  
supp2A) S. aureus Xen36 is used to check the possibility of TIVAP colonization through 24	  
the venous system.  25	  
supp2B) Overnight grown S. aureus Xen36 culture is used as inoculum. An inoculum of 26	  
5 X 108 cells of S. aureus Xen36 is centrifuged, washed and resuspended in 500µL 1X 27	  
PBS. 28	  
supp2C) Anesthetize the rat as described above. In case using chemical anesthesia, 29	  
inject only 200µL intraperitoneally as the procedure takes only 10 minutes for injection. 30	  
supp2D) Clean the tail with 70% ethanol and rub the tail with a sterile cotton swab to 31	  
remove the dead scales. Approximately 5cm above the tail end, inject bacteria into the 32	  
bloodstream of rat (already containing implanted TIVAP) through the lateral tail vein. 33	  
supp2E) Monitor rat before and after injecting bacteria for bioluminescence using IVIS-34	  
100 imaging system to check infection and colonization. 35	  
supp2F) 3-days after the injection euthanize rats as described earlier in the protocol. 36	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supp2G) TIVAP is removed aseptically to confirm the colonization by bioluminescence 1	  
and plating CFU/mL. 2	  
supp2H) 1-cm tip of the catheter is plated for CFU enumeration as the bacteria colonized 3	  
only the tip of catheter. 4	  
	  5	  
supp3) Immunosuppression of rats: (TIMING ~15-20 min per rat) 6	  
supp3A) Rats are injected intraperitoneally with cyclophosphamide.  7	  
CAUTION: cyclophosphamide is toxic and immunosuppressant. Cyclophosphamide is an 8	  
antineoplastic (anti-cancer) drug categorized as an alkylating agent. Its side effects depend 9	  
upon dosage such as lowered blood counts, sterility in males and females, pregnancy 10	  
defects and or discoloration of skin and nails. Using the chemical hood and gloves is highly 11	  
recommended when using this compound. For detailed literature on side effects, consult: 12	  
http://www.ncbi.nlm.nih.gov/pubmed/?term=Cyclophosphamide+side+effects 13	  
supp3B) Dose and regimen of cyclophosphamide delivery are optimized by estimating blood 14	  
total leukocyte count as determined using an animal blood cell counter (Vet abc, SCIL, 15	  
Germany ABC vet 2.0, Germany). Furthermore, immunosuppressed status of rats is 16	  
indicated by the physical state of rats such as lack of appetite, reduced weight and loss of 17	  
hair. One hundred mg/kg body weight of cyclophosphamide was finally selected for giving 18	  
intraperitoneal injections to rats (n= 4 for each bacterial strain) on day -4 and 50 mg/kg on 19	  
day -1 of inoculation.  20	  
Critical step: An optimized inoculum dose of 102 CFU/ 50µL 1X PBS for all bacterial strains 21	  
(higher inoculum doses lead to the death of animals overnight) is used for TIVAP 22	  
contamination and is confirmed by plating for CFU/mL. Control catheterized and 23	  
immunosuppressed rats receive 50µL 1X PBS only.  24	  
supp3C) Prior to inoculation of clinical strains, all rats are checked for the absence of 25	  
infections as for immune-competent rats. 26	  
	  27	  
4) Electron microscopy: (TIMING ~30 min per rat) 28	  
4A) After aseptic removal of colonized TIVAP from rats, 1 cm catheter of the catheter tip is 29	  
cut and the septum is dissected from the port using a scalpel. 30	  
 31	  
4B) Septum and catheter pieces are washed twice in cacodylate solution prepared with 32	  
gloves and under a chemical hood (0.07 M: 10.5mL 0.2M Na-cacodylate pH 7.4 + 19.5 mL 33	  
sterile D/W) and then fixed in EM fixative solution (for example, a mixture v/v/v of 6% 34	  
glutaraldehyde, 0.15% Ruthenium red, 0.2M Na-cacodylate pH 7.4).  35	  
	   25	  
CAUTION: Na-Cacodylate is a derivative of arsenic. It is highly toxic when inhaled, ingested, 1	  
or put in contact with skin or eyes. It is described as a possible carcinogen and teratogen. 2	  
Using the chemical hood and gloves is highly recommended when using this compound. 3	  
 4	  
4C) Inner lumen of the catheter and face of the septum inside the port are used to visualize 5	  
biofilm formation. 6	  
 7	  
4D) Samples are stored at 4°C until sent for microscopy to the core facility / experts (not 8	  
more than 10 days). 9	   	  10	  
5) In vivo lock therapy :  11	  
Antibiotics and their concentration for lock therapy studies were chosen based on 12	  
recommendations made by IDSA guidelines 4 (Table 1). Efficacy of cefazolin (5,000mg/mL in 13	  
5000IU/mL heparin) and gentamicin lock therapies (1.0mg/mL, or 5mg/mL), EDTA 14	  
(30mg/mL), ethanol (70%), L-arginine (0.4%) alone or in combination is evaluated against 15	  
bioluminescent E. coli 55989, P. aeruginosa PAK, MSSA S. aureus Xen36, MRSA S. aureus 16	  
Xen30 and S. epidermidis Xen43 27,28,30. Since 30% mortality was observed associated with 17	  
antibiotic lock therapy 27, this therapy is always used in conjunction with systemic 18	  
vancomycin hydrochloride (50mg/kg, for MSSA, MRSA, and S. epidermidis) or gentamicin 19	  
(30mg/kg, for Gram-negative bacteria) subcutaneous injections 42,43. The 4-day-old biofilm 20	  
formed inside the implanted TIVAP is locked (200µL) with the above-discussed antibiotics 21	  
and monitored for biofilm clearance by measuring bioluminescence. Two types of regimen 22	  
are followed for lock therapy: first is a 5-day lock regimen during which the old lock is 23	  
replaced by a new one every 24 h for 5 days in conjunction with systemic treatment for 5 24	  
days. We also assess 1 day lock regimen with a single instillation dwelling for 7 days in 25	  
conjunction with 1 day of systemic treatment. Rats with a colonized TIVAP but receiving PBS 26	  
lock are used as controls. 27	  
 28	  
5A) Anesthetize infected rat and measure the bioluminescence as described above after 4 29	  
days of infection in TIVAP. 30	  
 31	  
5B) Rat is transferred in the hood for instilling antibiotic solution in the TIVAP. Instill 200 µL 32	  
antibiotic solutions in the port slowly. Vancomycin or gentamicin for Gram positive and Gram 33	  
negative bacteria respectively is injected intraperitoneally to prevent systemic infection due to 34	  
flushing of the lock into the blood circulation. 35	  
 36	  
5C) Replace the lock every 24 h.  37	  
	   26	  
Critical step: It is possible that TIVAP may be blocked because of biofilm formation and old 1	  
lock may not be retrievable. In this case flush the old lock with PBS and then instill the fresh 2	  
lock in the port. 3	  
 4	  
5D) Monitor biofilm clearance by bioluminescence imaging every day before replacing the 5	  
lock. 6	  
 7	  
5E) Euthanize rats after day 7 of the last lock instillation for estimating viable cell counts and 8	  
electron microscopy analyses as described above. 9	  
 10	  
5F) In case of immunosuppressed rats, they are sacrificed on day 3 post-lock instillation. 11	  
	  12	  13	  
	   27	  
TIMING 1	  
 2	  
Step1: day -6 to day-1 (6 days) 3	  
Step2: 1-2 days (step 2A to 2E.19: ~55 min per rat per day and step2D: could be done in 4	  
parallel with step 2A) 5	  
Step3: 4 days; 3A to 3C: ~10 min per rat per day 6	  
Step 4A to 4J: 2 days; ~30 min per rat (Inoculum is started a day before the challenge) 7	  
Step A to 5C ~30 min per rat.  8	  
Step 5C.1 /5C.2: ~10 min per rat 9	  
Step 6A to 6E ~45 min per rat 10	  11	  
	   28	  
TROUBLESHOOTING  1	  
	  2	  
Step Trouble/problem Possible reason(s) Solution 
2E.14 Catheter blocked 
while inserting 
inside the vein. 
Catheter pushed into 
the wrong direction 
and entering the right 
axillary vein. 
Pull the catheter out slightly 
and gently rotate it while inside 
the jugular vein. Push the 
catheter gently in the right 
direction. 
2E.15 No Blood reflux 
during surgery. 
a) Catheter too long 
or too short. Catheter 
length is optimized to 
be ~4.5cm to reach 
exactly the tip of the 
right atrium. Longer 
catheter will reach 
inferior vena cava or 
enter the rat’s heart.  
 
b) The slanting cut 
made for inserting 
the catheter has 
bigger angle. Too 
slant cut will result in 
pulling the vein 
against it due to 
pressure and thus 
blocking the blood 
draw. 
a) Pull the catheter out of the 
vein slowly. Press the vein with 
a wet gauze pad to prevent 
blood loss and prevent the 
hydration of vein. Check the 
length of the catheter and cut it 
to the right length.  
If the catheter is shorter, than 
try to change the position of 
the port so that some length 
can be gained by reducing the 
distance between the port and 
the vein (in this case one may 
have to optimize the dead 
volume to avoid flushing of 
bacteria into the blood stream 
at the time of challenge). 
 
b) Pull out the catheter as 
above and make the right cut 
and reinsert it. 
3B.8 TIVAP not patent 
during post-
surgery 
maintenance. 
a) The cut made on 
the catheter to insert 
was too slanting. 
b) The catheter 
slipped out of the 
vein due to loosely 
tied thread to secure 
it in the vein. 
c) Flushing was not 
done properly 
resulting in blood 
a) Normally, it is not advisable 
to make a bigger slant for the 
ease of insertion but one can 
try to lift the rats from the back 
slight to open the channel or 
try to gently and slightly move 
the catheter without pulling it 
out of the vein. 
b) If the catheter has slipped 
out of the vein, rat must be 
excluded from the study. 
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clotting inside the 
TIVAP. 
c) These catheters (rats) are 
unusable for the study unless 
until comparing coating 
materials for patency. 
3C Local inflammation 
at the site of port 
implantation after 
surgery. 
a) Incision too deep 
 
b) Too much injury to 
the port area 
a) Only 1-2cm incision should 
be made. Pulling the skin 
outwards while making the 
incision prevents deep 
incisions.  
b) Training is required to keep 
the injuries to minimum. 
5B No signals after 
infection. 
a) Acquisition time 
was short 
b) Biofilm formed is 
not enough to 
capture the signals. 
c) Bioluminescence 
produced by the 
strain used is too 
low. 
a) Increase the time of 
acquisition up to 4 minutes. In 
this case acquire the 
bioluminescence for control 
rats also for longer time to 
avoid background. 
b) Biofilm capacities of 
different species and strains 
can vary. Detailed 
characterization of in vitro 
biofilm capacities can be 
performed. Time for 
bioluminescence acquisition 
can be adapted to in vitro 
biofilm capacities. 
c) The bioluminescence signal 
produced by bacteria must be 
high in order to be visible 
through the skin of the rat and 
through the TIVAP. 
Measurement of 
bioluminescence during in vitro 
biofilm formation within TIVAP 
can be performed to ensure 
that it is strong enough to be 
detected. 
 
6E.6 No biofilm 
formation at the 
a) Bacterial inoculum 
may not be enough 
a) Bacterial inoculum 
optimization maybe needed for 
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end of the study. to form biofilm 
b) Time required for 
bacteria to adhere 
maybe longer. 
c) Different catheters 
may behave 
differently. 
d) Contamination on 
the catheters can 
prevent biofilm 
formation. 
your bacterial strains. 
b) Increase the time to remove 
planktonic bacteria after 
injecting inoculum. 
c) TIVAP properties may 
change from lot to another. So, 
try changing the lot used. 
d) Contamination from the rat 
flora can prevent biofilm 
formation of your strain. 
Disinfect the skin of the rat 
properly to avoid any external 
contamination. 
 1	  
Table 2. TROUBLE SHOOTING  2	  
 3	  4	  
	   31	  
 1	  
ANTICIPATED RESULTS 2	  
1. Luminescent signals corresponding to bacterial colonization can be measured 3	  
within 3 h after the injection of inoculum for E. coli and P. aeruginosa. For S. aureus, the 4	  
luminescent signal can be measured after 24 h. Exposure time to measure the 5	  
luminescence can vary between bacterial strains. Normally, 1 min of exposure is 6	  
sufficient to detect measurable signals for bioluminescent variant strains (used in the 7	  
study) of E. coli 55989 and P. aeruginosa PAK but one can expect an exposure time of 8	  
2-4 minutes for S. aureus Xen36 27. For S. epidermidis Xen43 bioluminescence signals 9	  
were not obtained for any concentration of inoculum. One can expect to harvest ~7.6 to 10	  
8.3-log CFU/mL (port) and ~7.5 to 9.2-log CFU/mL (catheter) of biofilm biomass from 11	  
TIVAP after 10d of infection. Increase in biofilm-associated bioluminescence could be 12	  
measured up to day 120 post-infection with signals reaching maximum on day 4. 13	  
Reduced signals were observed from day 8 onwards, indicating restriction of biofilms to 14	  
TIVAP colonization (Figure 5) 27. These results can be correlated to the bloodstream 15	  
infection as indicated by presence of bacteria on day 4 whereas clearance of bacteria 16	  
from the peripheral blood by day 8. Thus, this model allows non-invasive study of chronic 17	  
biofilm infection. 18	  
 19	  
2. In case of immunosuppressed rats, severe pathology can be seen as indicated 20	  
by weight loss, fever and high bioluminescence as function of systemic biofilm infection 21	  
leading to death of animals by day 3 (Figure 6) 27. The blood and organ samples show 22	  
high bacterial load compared to immune-competent rats. 23	  
 24	  
3. In case of lock therapy experiments, the absence of bioluminescence may be 25	  
observed just after 1 instillation of antibiotic solution, such as in case of 26	  
gentamicin+EDTA lock. On contrary, this bioluminescence signals indicating presence of 27	  
persistent bacteria in the catheter may be seen as in case of gentamicin, EDTA, L-28	  
arginine alone (Figure 7) 28. Lock therapy may lead to bloodstream and systemic 29	  
infection in some rats. Thus, use of systemic treatment in conjunction with lock therapy is 30	  
required. 31	  
 32	  
4. In addition to biofilm pathogenesis, molecular mechanisms associated with 33	  
biofilm can be studied 29. It was shown using mutants of a bioluminescent variant of E. 34	  
coli 55989 that lipid A palmitoylation did not affect the bacterial adherence to catheters 35	  
but enhanced the in vivo biofilm survival. Moreover, the palmitoylation lead to reduced 36	  
	   32	  
cytokine trigger in vivo in rat model indicating role of palmitoylation in evading host 1	  
defenses 29. 2	  
 3	  
5. Modified TIVAP coated with methylcellulose and PEG was used to evaluate 4	  
prevention of adhesion of P. aeruginosa and S. aureus using the rat model and thus, 5	  
biofilm inhibition (Figure 8) 26. 6	  
	  7	  
	   33	  
 1	  
Microorganism Gentamicin 
(30mg/mL) 
Cefazolin 
(5mg/mL) 
EDTA 
(30mg/mL) 
Ethanol 
(70%) 
Gentamicine+EDTA 
(5mg/mL+30mg/mL) 
Gentamicine 
+Cefazolin 
(1mg/mL+ 5mg/mL) 
E. coli Y N.D. Y N.D. Y N.D. 
P. aeruginosa Y N.D. Y N.D. Y N.D. 
MSSA N.D. Y Y Y Y Y 
MRSA N.D. N.D. Y N.D. Y N.D. 
S. epidermidis N.D. N.D. Y N.D. Y N.D. 
Y: Efficacy tested, N.D.: efficacy not tested 2	  
Table 1: Lock therapy concentration (mg/mL) 3	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LEGENDS TO FIGURES: 1	  
 2	  
Figure 1. Schematic representation of the different steps of the in vivo model of 3	  
totally implantable venous access port related infection. Steps in black boxes 4	  
correspond to regular procedures of implantation, contamination and monitoring of 5	  
colonization. Steps in yellow boxes correspond to potential procedures that can be 6	  
applied to the regular model. 7	  
 8	  
Figure 2. TIVAP surgical implantation. TIVAP were surgically implanted in CD/SD 9	  
(IGS: Crl) rats. Surgery was performed under laminar air flow using a surgical hood and 10	  
aseptic conditions were maintained throughout the surgical procedure. For ease, labels 11	  
in figure correspond to steps described in the procedure under surgery section. (2A) Rat 12	  
was briefly kept in an isoflurane box to calm down and injected intraperitoneally with a 13	  
chemical anesthesia mixture to complete sedation and analgesia before starting the 14	  
procedure. (2B.1 – 2B.2) Rat was shaved on dorsal side from the neck to the lower end 15	  
of thoracic vertebrae and along the neck line of ventral side. (2C) Disinfection of skin 16	  
using betadine soap and solution. (2D) Pre-surgical preparations. Instruments and 17	  
objects required during the surgery kept on a sterile sheet in the laminar air flow. (2E.2) 18	  
Incision was made along the dorsal line at the upper thoracic vertebrae. (2E.4.1 – 2E.4.2 19	  
1 – 2E.4.3) TIVAP inserted in the subcutaneous pocket and secured by sutures. (2E.5.1) 20	  
Huber needle inserted in the port. (2E.5.2) Rat flipped on its back. (2E.6) 1-1.5cm 21	  
Incision in neck region (2E.7.1 – 2E.7.2) Jugular vein exposed. Work on animals was 22	  
performed in compliance with French and European regulations on care and protection 23	  
of laboratory animals (European Commission directive 2010/63; French law 2013-118, 24	  
06th February, 2013). The protocols used in this study were approved by the ethics 25	  
committee of “Paris Centre et Sud N°59” (reference 2012-0045). 26	  
 27	  
Figure 3. TIVAP surgical implantation (contd.). (2E.8) Cotton threads inserted under 28	  
the jugular vein to secure catheter. (2E.10) Tunneling rod inserted for passing the 29	  
catheter under the skin from dorsal to ventral side. (2E.11) Catheter cut at a slant (inside 30	  
caption showing the correct cut). (2E.13) Jugular vein incised using micro spring 31	  
scissors. (2E.14) Dilation of jugular vein using forceps. (2E.14.1 to 2E.14. 5) Catheter 32	  
inserted in the jugular vein. (2E.15) Flush and draw blood to check patency of TIVAP. 33	  
(2E.17.1 – 2E.17.2) Surgical wounds closed by suturing ventral and dorsal incisions. 34	  
Work on animals was performed in compliance with French and European regulations on 35	  
care and protection of laboratory animals (European Commission directive 2010/63; 36	  
	   35	  
French law 2013-118, 06th February, 2013). The protocols used in this study were 1	  
approved by the ethics committee of “Paris Centre et Sud N°59” (reference 2012-0045). 2	  
 3	  
Figure 4: Bacterial inoculation and monitoring of biofilm formation using 4	  
bioluminescence. The bacterial inoculum is directly injected through the septum of the 5	  
TIVAP using a Huber needle and biofilm development is monitored using a CCD camera 6	  
imaging system allowing to measure bioluminescence. Below is shown an example of 7	  
the images obtained for the colonization of the TIVAP by a bioluminescent clinically 8	  
relevant strain of P.aeruginosa and showing the progressive biofilm development within 9	  
the TIVAP. Work on animals was performed in compliance with French and European 10	  
regulations on care and protection of laboratory animals (European Commission 11	  
directive 2010/63; French law 2013-118, 06th February, 2013). The protocols used in 12	  
this study were approved by the ethics committee of “Paris Centre et Sud N°59” 13	  
(reference 2012-0045). 14	  
 15	  
Figure 5. Biofilm formation in TIVAP was confirmed by scanning electron 16	  
microscopy (SEM). TIVAPs implanted in rats and inoculated with S. aureus, P. 17	  
aeruginosa or E. coli were harvest on day 5 post-infection and analyzed with scanning 18	  
electron microscopy. Arrows represent bacteria in biofilm; arrowheads, blood cells. (A) 19	  
TIVAP inoculated with S. aureus, (B) TIVAP inoculated with P. aeruginosa, (C) TIVAP 20	  
inoculated with E. coli. (E) Scanning electron microscopy to show P. aeruginosa biofilm 21	  
growing inside the lumen of implanted catheter with typical biofilm micro colonies. (F-G) 22	  
Magnified view: a P. aeruginosa micro colony showing typical biofilm structures. Work on 23	  
animals was performed in compliance with French and European regulations on care 24	  
and protection of laboratory animals (European Commission directive 2010/63; French 25	  
law 2013-118, 06th February, 2013). The protocols used in this study were approved by 26	  
the ethics committee of “Paris Centre et Sud N°59” (reference 2012-0045). 27	  
 28	  
Figure 6. Biofilm led to lethal infection in immunosuppressed rats. (A) TIVAP 29	  
implanted and cyclophosphamide-treated rats were injected with 102 CFU in 100mL of P. 30	  
aeruginosa into the port of TIVAP and photon emission was monitored up to day 3 to 31	  
evaluate biofilm formation and associated infection. (B) Bacterial load from different 32	  
organs aseptically removed from dead animals was analyzed, organs were 33	  
homogenized and were plated on LB agar for viable counts per mL. CFU results are 34	  
means +/- standard deviations. Number of rats (n) used in the experiment, n = 4. Work 35	  
on animals was performed in compliance with French and European regulations on care 36	  
	   36	  
and protection of laboratory animals (European Commission directive 2010/63; French 1	  
law 2013-118, 06th February, 2013). The protocols used in this study were approved by 2	  
the ethics committee of “Paris Centre et Sud N°59” (reference 2012-0045). 3	  
 4	  
Figure 7. In vivo lock therapy against Staphylococcus aureus biofilm in the 5	  
implanted TIVAP: 5-day regimen presented. 200µL high dose antibiotics solution was 6	  
instilled in TIVAP of rats (day 0) to treat methicillin sensitive S. aureus biofilm 7	  
colonization (n = 5). Lock therapy was associated with systemic vancomycin for S. 8	  
aureus. The lock was renewed every 24 h for 5 days, and its efficacy was monitored as 9	  
photon emissions. (A) Control rats with PBS lock. (B) 5 mg/mL gentamicin lock. (C) 30 10	  
mg/mL EDTA alone. (D) Combined gentamicin (5 mg/mL) and EDTA (30 mg/mL) lock. In 11	  
panels A to D, representative experiments are shown. (E-H) Rats were euthanized after 12	  
7 days of treatment, and TIVAP were harvested and monitored for photon emissions. (I) 13	  
Bacterial cells from TIVAP were harvested and plated on TSB agar for counts of 14	  
CFU/mL. CFU results are means +/- standard deviations. One-way analysis of variance 15	  
(ANOVA) with Graphpad Prism version 5.0c was used for statistical analysis. A P value 16	  
of <0.05 was considered significant, **** P <0.0001. Work on animals was performed in 17	  
compliance with French and European regulations on care and protection of laboratory 18	  
animals (European Commission directive 2010/63; French law 2013-118, 06th February, 19	  
2013). The protocols used in this study were approved by the ethics committee of “Paris 20	  
Centre et Sud N°59” (reference 2012-0045). 21	  
 22	  
Figure 8. Modified anti-adhesive totally implantable venous access port (TIVAP). 23	  
(A) Commercially available pediatric TIVAP used in the study, and dismantled TIVAP (a, 24	  
catheter; b and c, envelope of port; d, sealing ring of port; e, septum; f, titanium port) and 25	  
anti-adhesive molecules used to modify TIVAP parts. The catheter and septum were 26	  
modified using methylcellulose (MeCe) derivative and the titanium port was modified 27	  
using polyethylene glycol (PEG) derivative. (B) Rats with modified or unmodified 28	  
implanted TIVAPs were inoculated with 106 colony-forming units (CFUs) of 29	  
Staphylococcus aureus or 103 CFUs of Pseudomonas aeruginosa per 50µL of 1X 30	  
phosphate-buffered saline. Bacteria were allowed to adhere to the TIVAP endoluminal 31	  
surface for 3 hours (S. aureus) or 1.5 hours (P. aeruginosa) and biofilms were left to 32	  
form for 5 days, and TIVAP was extracted to measure bacterial biofilm colonization. 33	  
Viable bacteria were counted by plating on tryptic soy agar for S. aureus or lysogeny 34	  
broth agar for P. aeruginosa. (Control: unmodified TIVAP and Si-Ti: both silicone and 35	  
titanium modified). Statistical analysis was performed using 1-way analysis of variance 36	  
	   37	  
(ANOVA) with GraphPad Prism software (version 5.0c). Differences were considered 1	  
significant at P < 0.05. *P ≤ 0.01; **P ≤ 0.001. Work on animals was performed in 2	  
compliance with French and European regulations on care and protection of laboratory 3	  
animals (European Commission directive 2010/63; French law 2013-118, 06th February, 4	  
2013). The protocols used in this study were approved by the ethics committee of “Paris 5	  
Centre et Sud N°59” (reference 2012-0045). 6	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 Pros of the model   Cons of the model 
     
1 Clinically relevant  1 Labor intensive 
2 Only requires basic small animal surgical 
training 
 2 Requires a 1-3 month training to 
acquire optimal technical expertise 
3 Totally implanted and no requirement for 
external containments on the animal 
 3 Expensive   
4 Closed by a septum enabling controlled 
infections and reduced external uncontrolled 
contaminations  
 4 Require daily manipulation 
(flush/draw) to avoid thrombosis and 
clogging 
5 Allows the in vivo study of all clinically relevant 
catheter pathogens 
 5 Restricted use in rat due to difficulty 
to adapt for small-sized mice 
6 Allows in vivo biofilm monitoring over very long 
period (model of chronic infection) thus 
reducing the number of used animals 
   
7 Biofilm progression can be studied using 
luminescent bacteria or fungi (Candida sp.) 
  
8 Allows the evaluation of prophylactic and 
curative anti-biofilm approaches 
  
9 Allows the evaluation of the contribution of the 
host immune system in biofilm development 
  
	  2	  
Table 3. Advantages, limitations and adaptations:  3	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